Blog

Telehealth: Businessman analyzes data strategy with graph on digital screen. Remote monitoring, patient engagement, virtual consultations, health data security, cost reduction, technology integration.

The UK market presents a strategic opportunity for international HealthTech companies, particularly those from North America, due to its proximity to mainland Europe and the established expertise of its logistics and corporate partners.&nbsp; &nbsp;&nbsp; The European HealthTech M&amp;A market in 2025 is also experiencing a "cautious yet discernible rebound", characterised by a "flight to quality" where increasing deal values are observed despite a decline in deal counts.This environment, influenced by significant private equity "dry powder" and the transformative impact of emerging technologies like AI, makes strategic market entry a high-stakes, high-reward endeavor. &nbsp;&nbsp; However, the UK market also presents unique challenges that can impede a successful entry. The research notes that while the UK and US share a language, there are cultural differences to consider, such as a preference for a "more subtle approach" in marketing and a more "consensus-based decision-making process". These cultural norms can lead to a longer sales cycle than what North American companies may be accustomed to. In addition to cultural nuances, companies must navigate the legal and compliance landscape, including registering with Companies House, understanding UK employment law, and complying with taxation requirements like UK corporation tax and Value Added Tax (VAT). The provided research also highlights that certain products or ingredients permitted in the US may be banned in the UK, underscoring the need for specialised regulatory knowledge.The role of Nelson Advisors in UK market entry strategies is defined by a highly specialised, nuanced, and holistic advisory model. The firm is not a generalist M&amp;A broker but a strategic partner exclusively focused on the HealthTech sector. Its value proposition is built on three pillars: &nbsp;&nbsp; Niche Specialisation: The exclusive focus on HealthTech and its sub-segments, especially high-growth areas like Healthcare AI and Cybersecurity, provides a profound understanding of a complex, regulated industry that generalist firms cannot match.Practitioner-Led Expertise: The "Founders for Founders" approach, combining entrepreneurial and corporate finance backgrounds, allows the firm to provide advice that is both financially astute and operationally empathetic, fostering a deeper level of trust and strategic alignment with founder-led companies.Holistic Strategic Framework: The "Build, Buy, Partner, Sell" framework guides clients through a comprehensive assessment of their strategic options, ensuring that a decision to enter the UK market is made in the context of long-term shareholder value and market dynamics. &nbsp;&nbsp; For North American and European companies considering a UK market entry, the implications of this analysis are clear. Nelson Advisors is particularly well-suited for companies seeking a partner who can provide strategic guidance on more than just a transaction.&nbsp; &nbsp;&nbsp; The firm’s deep regulatory knowledge is invaluable for navigating the complexities of the UK and EU compliance landscape. Furthermore, for companies operating in the AI or cybersecurity spaces, a specialised partner with a proven track record is essential for accurately valuing assets and mitigating risks. In a market where a "flight to quality" is increasingly evident, Nelson Advisors LLP's qualitative leadership and specialised expertise offer a compelling alternative to larger, generalist firms, positioning it as a critical ally for achieving sustainable success in the UK HealthTech market.To discuss how Nelson Advisors can help your Healthtech or MedTech company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk</a>

Nelson Advisors partner with HealthTech and MedTech companies devising UK market entry strategies

Nelson Advisors partner Lloyd Price co-authored the Oxford University Venture Capital Network: Insights into Digital Health Report with Ava Chan - DPhil candidate in Biology, Ellena O’Keeffe - &nbsp;MSc in Applied Cancer Science, Sili (Bobby) Qiu - DPhil candidate in Organic Chemistry, Adriana Mordente - DPhil candidate in Biology, Aneshka Moudry - MChem Chemistry. &nbsp;&nbsp; About Oxford University Venture Capital Network (OXVC)&nbsp; &nbsp;&nbsp; The Oxford University Venture Capital Network (OXVC) is a network of start-up founders, investors, and entrepreneurial Oxford students, supported by Oxford Science Enterprises and Presidio Ventures. &nbsp; For many students and founders, venture capital is a mysterious, complex, and inaccessible industry. We’re here to demystify it.VCs shape the future of the world through their investments, changing how we socialise, bank, travel, access healthcare, and beyond. However, VC is one of the least diverse industries. Women constitute only 30% of VC personnel in the UK and ethnic diversity is low. We want to change that. &nbsp;&nbsp; We take raw student talent, ambition, and vision and work directly with VC funds to provide a grounding in the theoretical and practical aspects of funding innovative ideas through to profitable outcomes. We nurture future innovators. &nbsp;&nbsp; Insights into Digital Health Report &nbsp;&nbsp; Below is an executive summary of the Oxford University Venture Capital Network: Insights into Digital Health Report:&nbsp;Digital Health definitionWe define Digital Health as the development and use of digital technologies making their way into products and companies for the first time to improve health outcomes.Market, Innovation &amp; Funding Landscape &nbsp;&nbsp; The largest market for digital health is in North America, whereas the fastest growing market is in the Asia-Pacific region.&nbsp;The biggest innovation hotspots constitute London, followed by Oxford, Cambridge and Southampton.Technology and Segment Deep DivesWe provide in-depth market analysis into the digital health industry segmented into Data Collection &amp; IT, Diagnostics, Disease management and Digital therapeutics.&nbsp; &nbsp; Data Collection and IT &nbsp;&nbsp; As healthcare systems shift towards outcomes-based models, the demand for integrated data platforms that support personalised patient care, real-time data analytics, and efficient healthcare delivery is surging.&nbsp;New entrants in this space should focus on developing innovative, scalable health tech solutions that align with Value-Based Care principles, ensuring regulatory compliance and addressing unmet needs in patient care and data management.&nbsp;Market strategies should emphasise collaborating with existing healthcare players, demonstrate clear clinical and cost-efficiency outcomes and ensure seamless integration with existing healthcare systems.B2B segment to dominate the market due to increasing strategic collaborations and the building of verticals.Diagnostics (Point of Care Technology) The increasing prevalence of chronic diseases and an ageing population underscore the importance of Point of Care Technology (POCT) implementation into primary care clinics.Molecular diagnostics technology is the fastest-growing segment within POCT.POCT is a competitive market and could potentially limit product innovation and market expansion.&nbsp;The primary users and beneficiaries of POCT over the next five years will be doctors in hospitals and clinics, who demand a high volume of devices and consumables.Disease Management&nbsp; The CKD management market is large and growing, driven by technological innovation and increasing demand for advanced treatments.Regulatory approval in key markets like the US and UK is crucial for the adoption of new technologies.The field faces challenges such as treatment costs, access to care, and the complexity of disease management.Startups and investors active in this space have significant opportunities for innovation and growth, with the potential for lucrative exits through acquisitions or IPOs.This landscape scan provides a foundational understanding of the venture capital dynamics in the CKD management sector, highlighting the opportunities for innovation and investment in this critical area of healthcare.Digital Therapeutics (DTx)DTx has great potential, and it has a growing market. At the same time, the market is getting crowded and has a few regulatory hurdles.&nbsp;DTx can extend care to a wider group of people compared to traditional medicine.&nbsp;The main challenges include the lack of regulatory and cybersecurity infrastructure for this emerging field, and limited clinical adoption due to lack of awareness or education.&nbsp;Reimbursement model hinders DTx clinical translation as patients become hesitant to try out advanced technologies.&nbsp;DTx startups' go-to-market strategies need to address a broad range of stakeholders in the DTx ecosystem to gain successful market entry, and clinical adoption can be improved through digital health education.&nbsp;It is foreseeable that DTx will be integrated into emerging technologies such as smart implants and have greater emphasis on preventive care .To discuss how Nelson Advisors can help your MedTech or &nbsp;Healthtech company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk</a>

Nelson Advisors co-author the Oxford University Venture Capital Network 'Insights into Digital Health' Report

Silver Buck Advisory Board - Buccaneers &nbsp;&nbsp; Silver Buck is the UK's leading HealthTech PR and Digital Marketing agency. Silver Buck offers a diverse range of services covering PR, Digital Marketing, Social Media and Events for a range of clients looking to create awareness with NHS, Private Healthcare and Government audiences. &nbsp;&nbsp; Advisory board members are some of the most influential health IT, digital health and marketing individuals in the sector. Combined they are the force that is the Silver Buccaneers – pioneers, adventurers and visionaries. &nbsp;&nbsp; The advisory board members are Lloyd Price, Matt Hancock, Dr Lia Ali, Richard Corbridge, Dominic Cushnan, Sam Shah, Jon Hoeksma, Hassan Chaudhury, Rachel Murphy, Trishna Bharadia. &nbsp;&nbsp; <a data-mce-href="https://www.silver-buck.com" href="https://www.silver-buck.com" title="https://www.silver-buck.com" target="_blank" rel="noopener">https://www.silver-buck.com</a> &nbsp;&nbsp; Silver Buck&nbsp; &nbsp;&nbsp; Silver Buck specialise in crafting tailored strategies and campaigns designed to deliver targeted messages to the appropriate audiences, whether you’re a digital health start-up, B2C health app, NHS trust or a well-established health IT supplier. Our expertise ensures that the right messages reach the right individuals, from NHS CIOs and investors to patients. &nbsp;&nbsp; At Silver Buck, we tell it like it is, we listen to your unique challenges and goals, we hit the ground running and we have proven results. We’re highly flexible and agile in our approach, accommodating to the changing needs of growing companies.. &nbsp;&nbsp; Healthcare demands a different perspective and creative solutions balanced with subtle nuances that often only the healthcare community understand. We aspired to be the leading full-service agency that had walked in your shoes, understood your challenges and had the experience that meant we knew exactly how to solve them. &nbsp;&nbsp; From our foundations in strategic health teach PR, our multi-skilled agency team has grown to include renowned journalists, expert communicators, digital marketing specialists, branding gurus, and creative content creators. However, Silver Buck as an agency has always been synonymous with digital health PR.

Nelson Advisors joins HealthTech Advisory Board alongside Former Secretary of State for Health & Social Care  and Senior NHS England staff

Businessman holding medical icon for health insurance concept

There are several key differences in MedTech M&amp;A between Europe and the USA, primarily related to regulatory frameworks, deal structures and market dynamics.Regulatory Differences &nbsp;USA: The Food and Drug Administration (FDA) is a centralized authority with a predictable, though rigorous, regulatory pathway. The FDA has actively tried to make the U.S. an attractive market for new medical devices, particularly for innovative technologies like AI-enabled devices.&nbsp; &nbsp; Europe: The regulatory landscape in Europe has become more complex with the introduction of the EU Medical Device Regulation (MDR) in 2021. The MDR replaced the previous Medical Device Directive (MDD), making the approval process stricter, requiring more clinical data, and extending time-to-market. This has led some companies to prioritise U.S. market entry over Europe.Deal Structure Differences Purchase Price Adjustments: In the U.S., purchase price adjustments (PPAs) are almost universal, with buyers expecting to be compensated for shortfalls in working capital or cash. In Europe, "lock box" structures are more common, especially in competitive auctions.Earn-outs: While common in both markets, the metrics used for earn-outs differ. In the U.S., revenue-based earn-outs are more prevalent, whereas in Europe, EBIT/EBITDA is the preferred metric. Liability Caps: U.S. deals often have lower seller liability caps (10% or less of the purchase price), largely due to the widespread use of representations and warranties (R&amp;W) insurance. In Europe, liability caps are typically higher (25% to 50%), as sellers are more accustomed to bearing more risk, although R&amp;W insurance is becoming more common.Material Adverse Change (MAC) Clauses: MAC clauses are standard in nearly all U.S. deals, allowing a buyer to back out if the target company experiences a significant negative change between signing and closing. These clauses are rare in Europe.Dispute Resolution: In the U.S., litigation is the default for dispute resolution. In Europe, arbitration is much more common, particularly in cross-border transactions.Market Dynamics Profitability: U.S.-based MedTech companies generally have higher operating margins than their European peers. This is largely attributed to better access to the lucrative U.S. market, where medical device prices are typically higher due to a different healthcare system. Market Fragmentation: The European MedTech market is more fragmented, with a large number of small and medium-sized companies. In contrast, the U.S. market is larger and less fragmented. This can impact the scale of acquisitions and the types of companies being targeted.To discuss how Nelson Advisors can help your Healthtech company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a>

Key MedTech Merger and Acquisition differences between Europe and the USA

The most sophisticated AI model is worthless if it cannot seamlessly integrate into the complex, manual, and often chaotic workflows of a healthcare organisation. Owning the workflow means moving from being a standalone "tool" to an embedded, indispensable component of a daily process. This is the central argument of the new healthcare AI economy. "AI's value is not in its existence but in its application within a functional, human-centric system. This approach is evident in both administrative and clinical applications." &nbsp; In the administrative domain, AI-powered solutions are directly addressing the operational burdens that plague healthcare organisations, which are a major contributor to staff burnout.Clinical documentation and scribing provide a prime example. The startup Abridge has mastered this workflow by using an AI platform that listens to patient-provider conversations and automatically generates medically relevant summaries for care teams and patients. This solution directly addresses the administrative burden that leads to burnout, providing a tangible value proposition: Abridge has saved providers an average of two hours per day. &nbsp;&nbsp; Similarly, the GenAI-native platform Arintra automates medical coding from patient charts, which demonstrably reduces errors and claim denials. At a single health system, its implementation led to a 5.1% revenue increase and a 43% drop in claim denials, while cutting coding costs by about one-third. &nbsp; In clinical workflows, AI is being integrated to enhance, not replace, human expertise. In radiology, for example, AI platforms can analyse medical images and prioritise work lists based on suspected pathologies, ensuring that urgent cases receive timely attention. This automation enhances efficiency and diagnostic accuracy by integrating directly with radiology information systems and picture archiving and communication systems (RIS/PACS).In a published study in the Journal of the American Medical Association, an AI system achieved a diagnostic accuracy rate of 94% in detecting lung nodules, significantly outperforming human radiologists. Robot-assisted surgery, which captured the largest market share in 2024, demonstrates how AI improves surgical precision, leading to better patient outcomes and quicker recovery times.To discuss Healthcare AI and how Nelson Advisors can help your Healthtech company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a>

Healthcare AI: Beyond the Algorithm

Nelson Advisors Partner Lloyd Price invited to Judge the 'Digital Health Hub Foundation: Digital Health Awards 2025' at HLTH Event in Las Vegas in October 2025.The Digital Health Hub Foundation Awards @ HLTH spotlight the most innovative health tech companies transforming healthcare through technology. In 2025, we’re back with innovation-targeted categories, recognising the companies making the biggest impact. &nbsp;&nbsp; Each year, the competition attracts groundbreaking companies from around the world, with only the most impactful advancing to the final stage. Join us on this journey to explore new innovations and spotlight the most impactful companies transforming digital health."Our distinguished panel of judges, featuring top names from healthcare, AI, venture capital, and innovation, will soon begin the rigorous evaluation process to determine the quarterfinalists. "<a data-mce-href="https://www.digitalhealthhub.org/awards/2025/digital-health-awards" href="https://www.digitalhealthhub.org/awards/2025/digital-health-awards" title="https://www.digitalhealthhub.org/awards/2025/digital-health-awards" target="_blank" rel="noopener">https://www.digitalhealthhub.org/awards/2025/digital-health-awards﻿</a>

Nelson Advisors

Blog

Nelson Advisors partner with HealthTech and MedTech compa...

Nelson Advisors co-author the Oxford University Venture C...

Nelson Advisors joins HealthTech Advisory Board alongside...

Key MedTech Merger and Acquisition differences between Eu...

Healthcare AI: Beyond the Algorithm

Nelson Advisors to Judge the 'Digital Health Hub Foundati...